Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
All News
Article
Article
At #ACR20 three different medications are reviewed in different studies to decrease the immunogenicity of pegloticase – Methotrexate, Azathioprine and Mycophenolate Mofetil.
David Liew
Tweet
How do we dose maintenance rituximab in AAV to optimise B cell depletion but minimise hypogammaglob?
Drug levels may be the answer. In this cohort (n=61)
trough >550ng/mL: all B cell depleted
>1000ng/mL: all got hypogammaglob
very interesting concept!
#ACR20 ABST1438 @RheumNow https://t.co/0pcl0BW2Tv
sheila
Tweet
Data from BIOBADASER 3 showed that there was a ⬇ in the incidence of S. pneumonia-related infxns in RA pts on b/tsDMARD after receiving the stepwise combined vax scheme (conj+PS) @RheumNow #ACR20 abs1465 #VaccinesWork https://t.co/KlestmKfaO
Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9
1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap
Study of 351 SLE patients from Leiden shows that SLE with Neuropsychatric disease do not have a higher mortality than lupus without CNS disease; but do have higher mortality than gen. population #ACR20 Abstr#1264 https://t.co/CmBjfUj1Ur https://t.co/WYZQDaI4yt
ACR/AF JIA guidelines presented @ACR20:
👉Initiate DMARD early over NSAID monotherapy
👉Use SQ MTX> oral MTX > SSZ/LEF
👉add biologic preferred over triple DMARD
👉DON'T use chronic low dose steroids
👉combo biologic+DMARD > biologic monoRx
https://t.co/lwoFSTuV91
@rheumnow https://t.co/wzh2LCS0dN
David Liew
Tweet
Abatacept in IgG4-RD. Plausible, but does it work?
Pilot n=10 @MGHrheumatology
ABA +<4w PNL
Some hit, some miss - but mechanistic correlates of response: Tfh2, unswitched memory B cells.
Exploring new options (w real benefit) very welcome in IgG4-RD!
#ACR20 ABST1480 @RheumNow https://t.co/0saS941Lga
#ACR20 Dr. M. Crow on Lupus #StateofArtLecture reviews treatment of SLE:
1. HCQ is the foundation of Rx
2. keep pred <7.5mg/day
3. belimumab works better when given early in disease (<2 yrs)
4. combination Rx may be needed
@rheumnow https://t.co/6zh1xkLXgN
Both fat mass and fat free mass have an impact on the response to bDMARDs after 6 months of treatment in AS pts. No tx response changes w/ skeletal muscle mass, visceral fat as well as water components. #ABS1376 #ACR20 @RheumNow https://t.co/oIdE8qvJPp https://t.co/wlXFf8esey
5yr DESIR cohort data estimated incidence rate of uveitis at 1.3/100p-y; over five years, uveitis was associated w/ dactylitis, biologic and sacroiliac MRI inflammation. #ABS1304 #ACR20 @RheumNow https://t.co/qmXlY7PmBB
Important thoughts- how do we actually use the biologics in practice for the rare diseases that do not have many FDA approved options? @RheumNow #ACR20 abstract 1429 https://t.co/SsYC1kF5uv
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study https://t.co/Z91MhXJ5HK #gca #tocilizumab #pet what about the radiation?
The Use of Tocilizumab and Tofacitinib in Patients with Resolved Hepatitis B Infection: A Case Series https://t.co/2OBy0lxd6b #hepb #tocilizumab #tofacitinib no reactivation in resolved infection
Meral K. El Ramahi, MD
Tweet
Reducing Immunogenicity of Pegloticase (RECIPE) w/ concomitant use of MMF in pts w/ refractory gout is a phase II double blind RCT that shows sustained serum urate lowering effect in addition to decrease in monthly rate of flares. #ACRbest #Abst0952 @RheumNow Practice changing? https://t.co/Z7GwCXZftE
Meral K. El Ramahi, MD
Tweet
Based on RECIPE, how many of you will use MMF concomitantly with start of pegloticase in treating refractory gout patients? #ACR20 @RheumNow
Richard Conway
Tweet
Dr Khanna presents RECIPE RCT of MMF to reduce immunogenicity of pegloticase. Sustained urate response ≤6mg/dL at 24 weeks 68% with MMF compared to 30% in placebo. @rheumnow #ACR20 Abstr#952 #ACRbest https://t.co/64nN5AqK3W
